Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Builders FirstSource, Inc.BLDR · Entity 3725 | Director | September 10, 2026 | September 14, 2026 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | June 10, 2025 | June 11, 2025 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Builders FirstSource, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 20,221 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 583 · Balance 20,221 F1: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2026 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. |
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectBy Spousal Lifetime Access Trust | 14,593 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,593 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2026 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy.
Indaptus Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-06-10 | Direct | 12,500 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The stock option vests and becomes exercisable on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on June 10, 2026.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Patheon N.V.
Report date August 29, 2017 · Filed August 30, 2017
Section 16 reporting ended · disclosed 2017-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Ordinary Shares)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 1
1 source rowRow 1 · 2017-08-29 · Other · Disposed 17,447 · Balance 0 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4: This amount includes 6,229 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2)
F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3)
F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer.
F4: This amount includes 6,229 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-390546 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,221 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2026 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 508 | $76.26 | $38,740.08 |
DisclosureSEC source: 0001193125-26-253455 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,638 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2026 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:30 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228998 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,130 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on May 14, 2027 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 371 | $104.29 | $38,691.59 |
DisclosureSEC source: 0001193125-26-088138 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,572 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 345 | $112.23 | $38,719.35 |
DisclosureSEC source: 0001193125-25-306905 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,201 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 279 | $138.68 | $38,691.72 |
DisclosureSEC source: 0001320940-25-000005 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,856 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014691 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 359 | $107.68 | $38,657.12 |
DisclosureSEC source: 0000950170-25-080909 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,577 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| May 27, 2025 Filed May 29, 2025 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 1,707 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078923 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,218 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on May 27, 2026 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $355.20 | $125.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 3 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $388.64 | $125.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 2 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.50 Strike: $24.60 | $250.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| March 01, 2025 Filed Mar 18, 2025 20:04 UTC Amendment | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 269 | $138.99 | $37,388.31 |
DisclosureSEC source: 0000950170-25-041131 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,511 F1 · date: This amendment reflects the correct transaction date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 269 | $138.99 | $37,388.31 |
DisclosureSEC source: 0000950170-25-031976 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,511 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 201 | $186.47 | $37,480.47 |
DisclosureSEC source: 0000950170-24-132740 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,242 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 23:25 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 215 | $174.00 | $37,410.00 |
DisclosureSEC source: 0000950170-24-103589 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,041 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 21:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-24-023151 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 6, 2025. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 22:30 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 1,194 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068953 · ownership.xml · nonDerivative · entry 2 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,826 F2 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 4, 2025 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 22:30 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 233 | $160.79 | $37,464.07 |
DisclosureSEC source: 0000950170-24-068953 · ownership.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,632 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 187 | $199.98 | $37,396.26 |
DisclosureSEC source: 0001209191-24-004430 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,399 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 269 | $139.28 | $37,466.32 |
DisclosureSEC source: 0001209191-23-057525 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,212 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 252 | $148.74 | $37,482.48 |
DisclosureSEC source: 0001209191-23-048506 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,943 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 1,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038049 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,691 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 14, 2024 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:00 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 323 | $115.86 | $37,422.78 |
DisclosureSEC source: 0001209191-23-034570 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,245 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001493152-23-019463 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on May 25, 2024. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:01 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 378 | $85.76 | $32,417.28 |
DisclosureSEC source: 0001209191-23-016014 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,922 F1 · shares: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:15 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 509 | $63.73 | $32,438.57 |
DisclosureSEC source: 0001209191-22-059663 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,544 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 14, 2023 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001493152-22-027431 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2032-09-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on September 30, 2023. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 553 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048715 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,035 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 14, 2023 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 2,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037504 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,512 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 14, 2023 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 509 | $63.81 | $32,479.29 |
DisclosureSEC source: 0001209191-22-033972 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,790 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 444 | $73.05 | $32,434.20 |
DisclosureSEC source: 0001209191-22-015378 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,281 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 02, 2021 Filed Feb 1, 2022 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GiftCommon Stock, par value $0.01 per share | 14,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005883 · doc5.xml · nonDerivative · entry 2 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spousal Lifetime Access Trust Disclosed balance after: 14,593 Read SEC document |
| December 02, 2021 Filed Feb 1, 2022 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GiftCommon Stock, par value $0.01 per share | 14,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005883 · doc5.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,922 Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 462 | $70.22 | $32,441.64 |
DisclosureSEC source: 0001209191-21-067786 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,515 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 606 | $53.59 | $32,475.54 |
DisclosureSEC source: 0001209191-21-054732 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,053 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 21:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001493152-21-018905 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2031-08-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on August 4, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:06 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 3,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041402 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,447 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 15, 2022 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:06 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 730 | $44.47 | $32,463.10 |
DisclosureSEC source: 0001209191-21-037613 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,988 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 766 | $44.84 | $34,347.44 |
DisclosureSEC source: 0001209191-21-015839 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,258 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:05 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 800 | $35.93 | $28,744.00 |
DisclosureSEC source: 0001209191-20-061119 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,492 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:47 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 928 | $30.98 | $28,749.44 |
DisclosureSEC source: 0001209191-20-049503 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,692 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001213900-20-017809 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2027-07-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:40 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 5,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037607 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,763 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on June 17, 2021 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:59 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 1,090 | $21.50 | $23,435.00 |
DisclosureSEC source: 0001209191-20-033687 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,923 F1 · kind: Reflects acquisition of shares in lieu of cash compensation for services as a director under the Corporation's 2014 Incentive Plan pursuant to the Corporation's Amended and Restated Director Compensation Policy. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:39 UTC | Builders FirstSource, Inc. BLDR · Entity 3725 | GrantCommon Stock, par value $0.01 per share | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053294 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,833 F1 · shares: Reflects the acquisition of restricted stock units pursuant to the Corporation's 2014 Incentive Plan. The restricted stock units vest on October 14, 2020 and entitle the reporting person to one share of common stock for each restricted stock unit that vests. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:36 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001213900-19-011964 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2026-06-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on June 28, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through June 28, 2022. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 19:03 UTC | Patheon N.V. PTHN · Entity 173467 | OtherRestricted Stock Units (Ordinary Shares) | 17,447 | $35.00 | $610,645.00 |
DisclosureSEC source: 0001209191-17-050805 · doc4.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · kind: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · kind: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4 · shares: This amount includes 6,229 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer. F1 · price: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · price: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · price: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 13:38 UTC | Patheon N.V. PTHN · Entity 173467 | GrantRestricted Stock Units (Ordinary Shares) | 6,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001320940-17-000002 · wf-form4_149063629539577.xml · nonDerivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,447 F1 · shares: On March 23, 2017, the reporting person was granted restricted stock units which will vest in full on the one-year anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 15:51 UTC | Patheon N.V. PTHN · Entity 173467 | Tax withholdingOrdinary Shares | 687 | $25.61 | $17,594.07 |
DisclosureSEC source: 0001643848-16-000016 · wf-form4_147811627320828.xml · nonDerivative · entry 2 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,218 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.